S&P 500   2,580.58 (-1.75%)
DOW   21,965.05 (-1.62%)
QQQ   189.67 (-1.23%)
AAPL   252.15 (-1.04%)
FB   166.86 (+0.55%)
MSFT   157.74 (-1.55%)
GOOGL   1,152.36 (+0.53%)
AMZN   1,949.55 (-0.73%)
CGC   14.25 (-1.45%)
NVDA   259.90 (-2.14%)
BABA   192.35 (+1.24%)
MU   42.36 (-4.87%)
GE   7.83 (-0.76%)
TSLA   516.50 (+2.86%)
AMD   45.51 (-5.11%)
T   29.21 (-3.37%)
ACB   0.90 (+1.13%)
F   4.78 (-4.98%)
NFLX   367.59 (-0.24%)
BAC   21.00 (-4.72%)
GILD   73.86 (-2.73%)
DIS   96.70 (-3.11%)
S&P 500   2,580.58 (-1.75%)
DOW   21,965.05 (-1.62%)
QQQ   189.67 (-1.23%)
AAPL   252.15 (-1.04%)
FB   166.86 (+0.55%)
MSFT   157.74 (-1.55%)
GOOGL   1,152.36 (+0.53%)
AMZN   1,949.55 (-0.73%)
CGC   14.25 (-1.45%)
NVDA   259.90 (-2.14%)
BABA   192.35 (+1.24%)
MU   42.36 (-4.87%)
GE   7.83 (-0.76%)
TSLA   516.50 (+2.86%)
AMD   45.51 (-5.11%)
T   29.21 (-3.37%)
ACB   0.90 (+1.13%)
F   4.78 (-4.98%)
NFLX   367.59 (-0.24%)
BAC   21.00 (-4.72%)
GILD   73.86 (-2.73%)
DIS   96.70 (-3.11%)
S&P 500   2,580.58 (-1.75%)
DOW   21,965.05 (-1.62%)
QQQ   189.67 (-1.23%)
AAPL   252.15 (-1.04%)
FB   166.86 (+0.55%)
MSFT   157.74 (-1.55%)
GOOGL   1,152.36 (+0.53%)
AMZN   1,949.55 (-0.73%)
CGC   14.25 (-1.45%)
NVDA   259.90 (-2.14%)
BABA   192.35 (+1.24%)
MU   42.36 (-4.87%)
GE   7.83 (-0.76%)
TSLA   516.50 (+2.86%)
AMD   45.51 (-5.11%)
T   29.21 (-3.37%)
ACB   0.90 (+1.13%)
F   4.78 (-4.98%)
NFLX   367.59 (-0.24%)
BAC   21.00 (-4.72%)
GILD   73.86 (-2.73%)
DIS   96.70 (-3.11%)
S&P 500   2,580.58 (-1.75%)
DOW   21,965.05 (-1.62%)
QQQ   189.67 (-1.23%)
AAPL   252.15 (-1.04%)
FB   166.86 (+0.55%)
MSFT   157.74 (-1.55%)
GOOGL   1,152.36 (+0.53%)
AMZN   1,949.55 (-0.73%)
CGC   14.25 (-1.45%)
NVDA   259.90 (-2.14%)
BABA   192.35 (+1.24%)
MU   42.36 (-4.87%)
GE   7.83 (-0.76%)
TSLA   516.50 (+2.86%)
AMD   45.51 (-5.11%)
T   29.21 (-3.37%)
ACB   0.90 (+1.13%)
F   4.78 (-4.98%)
NFLX   367.59 (-0.24%)
BAC   21.00 (-4.72%)
GILD   73.86 (-2.73%)
DIS   96.70 (-3.11%)
Log in

NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Forecast & News

$5.20
-0.31 (-5.63 %)
(As of 03/31/2020 03:30 PM ET)
Today's Range
$5.13
Now: $5.20
$5.57
50-Day Range
$3.44
MA: $5.00
$6.32
52-Week Range
$3.29
Now: $5.20
$8.09
Volume62,749 shs
Average Volume1.19 million shs
Market Capitalization$376.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Read More
Corbus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-197.69%

Miscellaneous

Employees77
Market Cap$376.95 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.


Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has increased by 26.2% and is now trading at $5.20. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Corbus Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Corbus Pharmaceuticals.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings data on Thursday, March, 12th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.05. The biopharmaceutical company had revenue of $2.57 million for the quarter, compared to analysts' expectations of $4.64 million. Corbus Pharmaceuticals had a negative net margin of 197.69% and a negative return on equity of 227.79%. View Corbus Pharmaceuticals' earnings history.

What price target have analysts set for CRBP?

4 brokerages have issued 1 year target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $18.00 to $112.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $44.25 in the next twelve months. This suggests a possible upside of 751.0% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News coverage about CRBP stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCorbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 44)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 61)
  • Dr. Mark A. Tepper, Co-Founder & Consultant (Age 62)
  • Dr. Barbara White, Chief Medical Officer (Age 69)
  • Ted Jenkins, Sr. Director of Investor Relations & Communications

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $5.20.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $376.95 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe. View additional information about Corbus Pharmaceuticals.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: S&P/TSX Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel